---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-070820"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:39:07.918462+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CorMedix reports Q3 net loss of $6.9M; provides DefenCath regulatory and NTAP updates

## Summary
- Net loss of $6.9M ($0.17 per share) improved from $8.6M loss ($0.22) in Q3 2021.
- Cash and short-term investments $59.0M; sufficient to fund operations through 2023.
- CMS increased NTAP reimbursement for DefenCath from $4,387.50 to $14,259.38 per visit.
- CMO implemented >95% of FDA corrective actions; NDA resubmission target end of Q1 2023.
- R&D expense decreased 51% to $2.3M; SG&A increased 21% to $4.6M on pre-launch activities.

## SEC filing metadata
- accession: 0001213900-22-070820
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/ea168353-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-070820
- JSON: https://secwatch.observer/filing/0001213900-22-070820.json
- Plain text: https://secwatch.observer/filing/0001213900-22-070820.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported the third quarter of 2022 results: net income $6.9 million, EPS $0.17 per share.
  - Period: the third quarter of 2022
  - Net income: $6.9 million
  - EPS: $0.17 per share
  - Result: reported results
  source text: For the third quarter of 2022, CorMedix recorded a net loss of $6.9 million, or $0.17 per share, compared with a net loss of $8.6 million, or $0.22 per share, in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm
- Earnings Releases
  CorMedix Inc. reported the nine months ended September 30, 2022 results: net income $21.5 million, EPS $0.54 per share.
  - Period: the nine months ended September 30, 2022
  - Net income: $21.5 million
  - EPS: $0.54 per share
  - Result: reported results
  source text: For the nine months ended September 30, 2022, CorMedix recorded a net loss of $21.5 million, or $0.54 per share, compared with a net loss of $20.4 million, or $0.54 per share, in the first nine months of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.